Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2020 - 2025)

Orchestra BioMed Holdings (OBIO) has 6 years of Non-Current Deffered Revenue data on file, last reported at $8.7 million in Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 24.3% year-over-year to $8.7 million in Q3 2025; TTM through Sep 2025 was $8.7 million, a 24.3% decrease from a year earlier, with the FY2024 full-year figure at $11.0 million, down 26.36% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $8.7 million, down from $9.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for OBIO reached as high as $14.9 million in Q4 2023 and fell as low as $5.6 million in Q1 2021.
• Historically, Non-Current Deffered Revenue has averaged $9.8 million across 5 years, with a median of $10.8 million in 2025.
• Across the five-year window, Non-Current Deffered Revenue jumped 147.23% in 2023 and decreased 26.36% in 2024, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $5.6 million in 2021, then jumped by 133.98% to $13.1 million in 2022, then advanced by 13.89% to $14.9 million in 2023, then decreased by 26.36% to $11.0 million in 2024, then retreated by 21.2% to $8.7 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $8.7 million in Q3 2025, $9.6 million in Q2 2025, and $10.8 million in Q1 2025.